Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Pre-Open Stock Movers 10/05: (AGFY) (RXDX) (FLUX) Higher; (UPH) (CMTL) (RIDE) Lower (more...)
October 5, 2021 9:23 AM EDTPre-Open Stock Movers:
UpHealth, Inc. (NYSE: UPH) 33.7% LOWER; announced the pricing of its previously announced underwritten public offering (the "Offering") of 23,000,000 shares of its common stock, par value $0.0001 per share (the "Common Stock"), at a public offering price of $1.75 per share.
After-Hours Stock Movers 10/04: (AGFY) (RXDX) (RYAM) Higher; (CMTL) Lower (more.
October 4, 2021 6:10 PM EDTAfter-Hours Stock Movers:
Agrify Corporation (Nasdaq: AGFY) 14.5% HIGHER; announced it has acquired Precision Extraction Solutions and Cascade Sciences, two of the leading brands that provide equipment and solutions for extraction, post-processing, and testing for the cannabis and hemp industry, from Sinclair Scientific.
Xenon Pharmaceuticals (XENE) Announces $250M Proposed Public Offering of Common Shares
October 4, 2021 4:08 PM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the... More
Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement
October 4, 2021 4:05 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) files mixed shelf registration statement of:
Common Shares
Preferred Shares
Warrants
Units
Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies
October 4, 2021 11:23 AM EDTJefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $45 at Wedbush, Following Clinical Business Update
October 4, 2021 11:04 AM EDTWedbush analyst Laura Chico raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $45.00 (from $24.00) while maintaining a Outperform rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $45 at Guggenheim, Following Clinical Business Update
October 4, 2021 10:51 AM EDTGuggenheim analyst Yatin Suneja raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $45.00 (from $30.00) while maintaining a Buy rating.
... MoreXenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel
October 4, 2021 10:39 AM EDTStifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.
The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More
Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)
October 4, 2021 9:25 AM EDTToday's Pre-Open Stock Movers:
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) 73% HIGHER; reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator... More
Xenon's (XENE) X-Tole Data as Good as it Gets with Best-in-Category Efficacy - Analyst
October 4, 2021 8:56 AM EDTEarlier today, Xenon Pharmaceuticals Inc. (Nasdaq: XENE) reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients with focal... More
Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint
October 4, 2021 7:01 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients... More
Xenon Pharmaceuticals (XENE) Halted, News Pending
October 4, 2021 6:55 AM EDTXenon Pharmaceuticals (NASDAQ: XENE) Halted, News Pending
... MoreXenon Pharmaceuticals (XENE) Schedules Webcast for October 4th, 7AM EST to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101
October 4, 2021 5:46 AM EDTXenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b X-TOLE clinical trial on Monday, October 4, 2021 at 7:30 am Eastern... More
